Observational Study to Observe the Safety of Levemir® Treatment in Patients With Type 2 Diabetes
NCT ID: NCT00735501
Last Updated: 2014-10-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
314 participants
OBSERVATIONAL
2008-03-31
2010-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Observational Study on Efficacy and Safety in Subjects Using Levemir® for the Treatment of Insulin Dependent Type 1 or Type 2 Diabetes
NCT00738153
Observational Study to Evaluate Safety of Levemir® in Type 1 and Type 2 Diabetes
NCT00700765
Evaluation of Levemir® for the Treatment of Type 1 and 2 Diabetes
NCT00655044
Observational Study to Evaluate the Safety of Levemir® in Diabetes
NCT00706017
Observational Safety Study in Subjects Using Levemir® (Insulin Detemir) for the Treatment of Type 2 Diabetes Mellitus
NCT00709475
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
insulin detemir
Start dose and frequency as well as dose alterations to be determined by the physician according to normal clinical evaluation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
insulin detemir
Start dose and frequency as well as dose alterations to be determined by the physician according to normal clinical evaluation
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Currently treated with basal human insulin therapy (basal only or in combination with oral glucose lowering drugs or other insulin)
* Selection of patients will be at the discretion of the treating physician after the decision to prescribe one of the study products to the patient
Exclusion Criteria
* Pregnancy or breastfeeding or intention of becoming pregnant within the next 6 months
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novo Nordisk A/S
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Global Clinical Registry (GCR, 1452)
Role: STUDY_DIRECTOR
Novo Nordisk A/S
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Copenhagen S, , Denmark
Stockholm, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Clinical Trials at Novo Nordisk
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NN304-1938
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.